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dissection: A long-term analysisG. Michael Deeb, MD,a Himanshu J. Patel, MD,a and David M. Williams, MDbAortic dissection remains themost frequent and lethal compli-
cation of thoracic aortic disease, and although advances in care
have demonstrated improved outcomes for patients with acute
aortic dissection, malperfusion remains a significant adverse
risk factor for survival for both acute type A and B aortic
dissection.1-4 Malperfusion syndrome is defined as the loss
of blood supply to a vital organ caused by branch arterial
obstruction secondary to the dissection. The result is end-
organ ischemia, with possible malfunction and infarction if
not corrected in a timely fashion. Malperfusion can be classi-
fied as both dynamic and static, depending on the anatomic
obstruction. Dynamic obstruction is secondary to the motion
of the intimal flapwithin the aortic lumen resulting fromhemo-
dynamic forces. The intimal flap may obstruct the orifice of
a branch vessel to a vital organ, causing ischemia with poten-
tial end-organ dysfunction and infarction. As a dynamic
phenomenon, malperfusion may vary depending on changes
in blood pressure and hemodynamic forces, and inmany cases
can be adequately managed with medical therapy: controlling
blood pressure and hemodynamics. If this fails, intervention is
needed. Static malperfusion is defined as dissection of the
branch vessel with obstruction of the true lumen. This form
of obstruction cannot be corrected with medical management
and will require interventional correction.5,6
Approximately one third of patients with type A dissec-
tion manifest malperfusion syndrome.7 If the malperfusion
is dynamic, restoration of true aortic luminal flow by elimi-
nating the tear and replacing the ascending aorta will often
correct the secondary malperfusion.8 With delayed diagno-
sis of dissection, however, established end-organ ischemia
and clinical deterioration are typical, and the conventional
strategy of immediate ascending aortic repair may be subop-
timal. In these situations, alternative management strategies
should be considered.From the Section of Cardiac Surgery,a Department of Surgery, and Section of Inter-
ventional Radiology,b Department of Radiology, University of Michigan, Ann
Arbor, Mich.
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operative delay for those patients presenting with acute type
A dissection, malperfusion, and ischemic end-organ dys-
function. In that study, a historical cohort of patients present-
ing with ischemic end-organ dysfunction from malperfusion
taken directly for open repair was compared with a cohort
managed with initial percutaneous fenestration, selective
branch vessel stenting, and delayed operative repair after
resolution of the perfusion injury. In contrast with an in-
hospital mortality of 89% for the historical group, those pa-
tients who underwent operative delay had an overall 25%
mortality, including a 15% mortality from rupture.9
These early results led to a consistent strategy for all
patients presenting with acute type A dissection with signif-
icant end-organ ischemia from malperfusion at our institu-
tion: restoring end-organ perfusion before operation. After
10 years, we reviewed this strategy to determine the out-
comes and the validity of the approach.Over that time period,
196 patients with acute type A dissection presented to the
University of Michigan Hospital, and 70 were diagnosed
with malperfusion and end-organ dysfunction. These pa-
tients underwent the strategy of percutaneous end-organ re-
perfusion and medical stabilization, followed by surgical
repair. There was a 95% success rate in opening obstructed
vessels percutaneously. Twenty-three patients (38%) died
before surgical repair, 12 (19%) of rupture and 11(19%)
of malperfusion complications. This was in stark contrast
with the 126 patients who did not have malperfusion or
end-organ dysfunction, whose early operative mortality
was 9.5%. Cumulative survival analysis showed that theme-
dian survival for the uncomplicated patients was 96 months,
whereas for the malperfused it was 54 months (P< .001).
An analysis was also undertaken to determine whether
malperfusion of any particular vascular bed was an indepen-
dent correlate of mortality: Mesenteric malperfusion was
statistically significant. We then analyzed the outcomes for
the uncomplicated patients versus the malperfused patients
who survived the percutaneous protocol and went on to op-
erative repair. This analysis was to determine whether cor-
rected malperfusion syndrome would have an adverse
impact on surgical outcomes once the syndrome had re-
solved. The analysis compared death, stroke, and need for
dialysis or tracheostomy between the 2 groups and found
no statistically significant difference. Cumulative survival
curves also showed no statistical significance, with uncom-
plicated patients having a median of 96 months of survival
versus 81 months for the malperfused patients who pro-
ceeded to surgery.10 It was concluded that presentation ofery c December 2010
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dysfunction is an important adverse factor for long-term sur-
vival, particularly in the setting of mesenteric malperfusion.
The strategy of immediate reperfusion, stabilization, and
planned operation still carries a significant risk for early
mortality (38%). Those patients who do survive the initial
malperfusion and undergo repair have no adverse effect
and have a similar operative and late survival when com-
pared with those presenting with uncomplicated dissection.
We believe it is important that the distinction is clearly
made between malperfusion and malperfusion with ische-
mia and end-organ dysfunction. Those patients with malper-
fusion but no significant adverse end-organ effects are best
treated with immediate surgical repair. An acute type A dis-
section is still a surgical emergency, and patients without
end-organ ischemia—both with and without malperfusion—
have an equal operative risk, which is significantly lower
than patients with malperfusion and end-organ dysfunction.
The International Registry of Acute Dissection recently
published data noting an in-hospital mortality of 13% for
all patients with acute type B dissection. Branch vessel in-
volvement or malperfusion was an independent predictor
of early death, with an odds ratio of 2.9 (P¼ .002).4 The op-
tions for patients with type B malperfusion are open surgical
repair, percutaneous fenestration, and bare-metal stenting to
create a reentry tear and establish reperfusion, and thoracic
endograft placement (TEVAR) to cover the primary tear.
Publications show that even with the latest surgical tech-
niques and accumulated experience, the early mortality for
those requiring operative repair ranges from 18% to
36%.4,11 The International Registry of Acute Dissection
published a 32% mortality.4
It was in this setting that we and others described a percuta-
neous endovascular solution of fenestration and stenting to re-
lieve end-organ ischemia from branch vessel compromise as
a potential method to improve early outcomes.5,6 Thoracic
endografting was soon proposed as an alternative solution
to open repair or percutaneous fenestration as a means to
resolve acute type B dissection with malperfusion.12 With
this approach, the entry tear is sealed by TEVAR and the dy-
namic obstruction is relieved. Associated static obstruction is
not treated by TEVAR and requires open revascularization or
branch vessel stenting. The benefits of TEVAR in this setting
include not only the exclusion of the entry tear and relief of
dynamic obstruction but also promotion of thrombosis of
the false lumen, with subsequent beneficial aortic remodeling,
possibly reducing the need for subsequent future operations
or rupture.
The demonstration of beneficial aortic remodeling after
TEVAR for aortic dissection with malperfusion was first
defined by Dake and colleagues,12 and later verified by
Rodriguez and the group from Arizona.13 Duebener and
colleagues,14 from Germany, reported results in 10 patients
with type B dissection and malperfusion in whom they hadThe Journal of Thoracic and Car90% success excluding the entry tear and reestablishing per-
fusion. However, they had a 20% mortality rate and a 30%
complication rate that required crossover to open surgery.
They concluded that TEVAR is a promising form of therapy,
but that refinements in stent design and application are
needed to improve the prognosis for these very sick
patients.14 Szeto and colleagues,15 from the University of
Pennsylvania, described the use of TEVAR for type B
complicated dissections in 35 patients. Seventeen of these
patients were treated for malperfusion: They reported no
operative mortality in this group and 94% 1-year survival.
However, long-term data in this study were lacking, and
the incidence of neurologic complications in the entire series
exceeded 10%.15 Feezor and colleagues,16 from Gainsville,
reported on the use of TEVAR for 33 patients with acute
complicated type B dissection. The 30-day in-hospital mor-
tality for their group was 21%, with 15% having permanent
spinal cord complications, 12% having renal failure requir-
ing dialysis, and a 12% incidence of stroke. They concluded
that TEVAR for complicated type B dissection was associ-
ated with significant mortality and morbidity, and that the
overall role for treatment should be better defined and
compared with other surgical and interventional options.16
We reported long-term results for percutaneous fenestration
with baremetal stenting to recreate a reentry tear and establish
reperfusion in patients with acute type B dissection with mal-
perfusion.17A cohort of 69 patientswas studied,with a techni-
cal success rate of 96%. Therewas a 17%mortality rate in this
group: 7% dying of false lumen rupture and 10% dying of
malperfusion complications. The incidence of stroke was
4.3%, and 14% required temporary dialysis, which resolved.
There was no paraplegia or spinal cord injury caused by the
procedure, and no retrograde aortic dissection. Kaplan–Meier
survival curves showed a 1-year survival of 76%; 5-year
survival was 65%, and 8-year survival was 55%. The
freedom from open repair or rupture was 80% at 1 year,
68% at 5 years, and 55% at 8 years, with a median time of
treatment failure at 80 months. The important limitation of
this approach is its inability to treat the risk of aortic rupture.
An acute type B dissection complicated by malperfusion
with end-organ dysfunction is an important adverse factor
for early and late survival. The strategies of percutaneous
therapy seem to improve survival when compared with his-
torical reports of both medical and surgical intervention.
TEVAR is an attractive percutaneous technique because it
eliminates the entry tear, reexpands the true lumen, allows
remodeling, and potentially markedly reduces the risk of
rupture. However, neurologic complications, trauma to the
aortic wall resulting in dissection, or rupture occur in signif-
icant numbers, and increased experience and long-term data
are needed to assess this therapy. The long-term data from
fenestration and stenting can be used for comparison to
evaluate TEVAR as a primary therapeutic modality in com-
plicated acute type B dissection.diovascular Surgery c Volume 140, Number 6S S99
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